Matthew C. Breeggemann

Matthew C. Breeggemann

Auto-generated profile, based on publicly available information

Matthew C. Breeggemann

Division of Nephrology, University of California San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKoichi Kikuchi
Koichi Kikuchi
DSDaisuke Saigusa
Daisuke Saigusa
YKYoshitomi Kanemitsu
Yoshitomi Kanemitsu
YMYotaro Matsumoto
Yotaro Matsumoto
PTPaxton Thanai
Paxton Thanai
TATakaaki Abe
Takaaki Abe
Diabetic kidney disease is a major cause of renal failure that urgently necessitates a breakthrough in disease management. Here we show using untargeted metabolomics that levels of phenyl sulfate, a gut microbiota-derived metabolite, increase with the progression of diabetes in rats overexpressing human uremic toxin transporter SLCO4C1 in the kidney, and are decreased in rats with limited proteinuria. In experimental models of diabetes, phenyl sulfate administration induces albuminuria and podocyte damage. In a diabetic patient cohort, phenyl sulfate levels significantly correlate with basal and predicted 2-year progression of albuminuria in patients with microalbuminuria. Inhibition of tyrosine phenol-lyase, a bacterial enzyme responsible for the synthesis of phenol from dietary tyrosine before it is metabolized into phenyl sulfate in the liver, reduces albuminuria in diabetic mice. Together, our results suggest that phenyl sulfate contributes to albuminuria and could be used as a disease marker and future therapeutic target in diabetic kidney disease.

7 July 2023 in Case Reports in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
MBMatthew C. Breeggemann
Matthew C. Breeggemann
SGStephen L. Gluck
Stephen L. Gluck
MSMarshall L. Stoller
Marshall L. Stoller
MLMarsha M. Lee
Marsha M. Lee
The primary hyperoxalurias (PHs) are a group of diseases characterized by kidney stones, nephrocalcinosis, and chronic kidney disease. At stages of advanced kidney disease, glomerular filtration of oxalate becomes insufficient, plasma levels increase, and tissue deposition may occur. Hemodialysis is often unable to overcome the excess hepatic oxalate production. The current surgical management of primary hyperoxaluria type 1 (PH1) is combined liver kidney transplantation. In a subset of PH1 patients who respond to pyridoxine, kidney-only transplantation has been successfully performed. Recently, kidney-only transplantation has also been performed in PH1 patients receiving a small interfering RNA therapy called lumasiran. This drug targets the hepatic overproduction of oxalate, making kidney-only transplantation a potentially practical novel approach for managing PH1 patients with advanced kidney disease. It is unknown if similar effects could be seen with a different small interfering RNA agent called nedosiran. This article will briefly review PH1, describe the small interfering RNA therapies being used to treat PH, summarize the reported cases of kidney-only transplantation performed with lumasiran, and detail a case of kidney-only transplantation performed in a PH1 patient receiving nedosiran.

18 March 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
MBMatthew C. Breeggemann
Matthew C. Breeggemann
PHPeter C. Harris
Peter C. Harris
JLJohn C. Lieske
John C. Lieske
GTGregory E Tasian
Gregory E Tasian
KWKyle D. Wood
Kyle D. Wood
An abstract is unavailable. This article is available as a PDF only.

31 January 2022 in Case Reports in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
MBMatthew C. Breeggemann
Matthew C. Breeggemann
SGStephen L. Gluck
Stephen L. Gluck
Hypokalemia is a relatively common electrolyte disorder usually resulting from gastrointestinal wasting. Transient hyperkalemia in those treated for hypokalemia has been previously described to occur in 16% of hospitalized patients. The majority of those patients had acute, hospital-acquired hypokalemia. Here, we report a case of a young man with alcohol use disorder and chronic hypokalemia who was hospitalized for muscle weakness, abdominal pain, and intractable emesis. His potassium was 2.5 mEq/L on the day of admission. Four days later, with a creatinine at baseline (0.9 mg/dL), potassium abruptly increased to 6.7 mEq/L. He did not have evidence of hyperaldosteronism. In cases of chronic hypokalemia, we propose that the adaptive mechanisms of the distal tubule with total body potassium deficits require time to revert back to a nonactive state and that transient hyperkalemia may be observed during these “refractory” periods during which potassium supplementation is continued. The time required for disassembly of with no lysine kinases following resolution of hypokalemia is unknown. Hyperkalemia is an important consideration when treating patients with chronic hypokalemia.

13 August 2026 in Kidney Medicine
Verified
Journal Article
Open access
MBMatthew C. Breeggemann
Matthew C. Breeggemann
MSMarshall L. Stoller
Marshall L. Stoller
SGStephen L. Gluck
Stephen L. Gluck